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SUMMARY 
 
Background 
Metamizole has been banned in several countries because of its toxicity, but it 
is still used in many countries as an over the counter drug due to its effective 
analgesic and antispasmodic properties. Although a large variability in the 
biodisposition of metamizole is known, factors underlying such variability are 
poorly understood. 
Methods. 
To assessing factor related to metamizole metabolic profiles, we analyzed the 
urinary recovery of metabolites, as well as the association of these profiles with 
genetic and non-genetic factors, in a group of 362 healthy individuals. 
Results. 
Gender, age, drinking habits and functional polymorphisms are strongly related 
to metabolic profiles. The N-demethylation of the active metabolite MAA is 
diminished in carriers of the CYP2C19*2 allele and in NAT2-slow acetylators. 
The acetylation of the secondary metabolite AA is decreased in men, in drinkers 
and in NAT2-slow acetylators with a differential effect of NAT2*5 and NAT2*6 
alleles. The formylation of MAA is diminished in older subjects and in carriers of 
defect CYP2C9 and CYP2C19 alleles. Two novel arachidonoyl metabolites 
were identified for the first time in man. Women and NAT2-slow acetylators 
show higher concentrations, whereas the presence of the rapid CYP2C19*17 
allele is associated with lower concentrations of these metabolites. All genetic 
associations show a gene-dose effect. 
Conclusions.  
We identified for the first time genetic and non-genetic factors related to the 
oxidative metabolism of metamizole, as well as new active metabolites. The 
phenotypic and genetic factors identified in this study can be used as putative 
biomarkers of metamizole biotransformation and response. 
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INTRODUCTION 
Metamizole ([N-(1,5-dimethyl-3-oxo-2-phenylpyrazolin-4-yl)-N-methylamino] 
methanesulfonate, dipyrone, drug bank id. no. DB04817) is a non-steroidal anti-
inflammatory drug (NSAID) commonly used for severe pain conditions, cancer 
pain and migraine as well as fever refractory to other treatments in several 
countries in Europe, Asia and South America. In other countries such as USA, 
UK and Canada, metamizole has been banned because it is associated with 
potentially fatal agranulocytosis  [1-3]    
Reported estimates of the risk of agranulocytosis associated to metamizole vary 
by several orders of magnitude, and are likely to be influenced by dose, 
duration and concomitant medication   [4-5]. In addition, in the countries where 
it is marketed, metamizole is the most frequent drug involved in selective 
hypersensibility response to NSAIDs, and most patients with selective 
hypersensitivity to metamizole develop anaphylaxis  [6-7]. 
Metamizole is a prodrug. After oral administration, it is rapidly hydrolyzed in the 
gastric juice to 4-methyl-amino-antipyrine (MAA). MAA is converted to 4-formyl-
amino-antipyrine (FAA), which is an end-product, and to 4-amino-antipyrine 
(AA), which further metabolized to 4-acetyl-amino-antipyrine (AAA) by the 
polymorphic enzyme Arylamine N-acetyl-transferase 2 [8-11]. Two metamizole 
metabolites, MAA and AA, inhibit cyclooxygenases 1 and 2 with different 
potencies, MAA is roughly nine-fold more potent COX inhibitor than AA and, for 
both metabolites MAA and AA the potency for COX1 inhibition is about twice as 
that for COX2 inhibition [3]. The involvement of metamizole metabolites in 
adverse drug effects is not well understood and whether the adverse effects are 
related to the parent drug or to metamizole metabolites remains to be 
elucidated. Because adverse effects of metamizole seem to be related to 
factors that modify drug exposure or pharmacokinetics [4-5], it could be 
hypothesized that variability in metamizole biotransformation may modify the 
risk of developing adverse effects with this drug. Indirect evidence support this 
hypothesis, since it has been shown that many patients with hypersensitivity to 
metamizole are negative to skin testing and to basophil activation with 
metamizole [6], and that NAT2 slow-acetylation haplotypes, that modify the 
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ability of acetylating AA, are associated with the risk of developing infant 
leukemia with maternal exposure to dipyrone during pregnancy [12]. 
The pharmacokinetics of metamizole in man has been studied in detail. MAA, 
AA, FAA and AAA are detected in plasma, urine, and cerebrospinal fluid, and 
large interindividual variability in the metabolic ratios leading to different 
metabolites have been reported [8-9, 11, 13-15]. However, little information is 
available on factors modifying the metabolic profiles after metamizole use. The 
widespread prescription or over-the-counter use in many countries requires 
insight into factors modifying metamizole metabolic profile. In this study, we 
analyzed the metamizole metabolic profiles in urine, as well as the occurrence 
of as yet unknown metabolites, in a large group of healthy subjects. The study 
aims to investigate non-genetic and genetic factors influencing metamizole 
metabolic profiles as well as to identifying biomarkers for different metabolic 
profiles that may be used to investigate putative factors leading to adverse drug 
reactions after metamizole use.  
 
 
 
  
5 
 
METHODS 
 
Participants. 
Three hundred and sixty two unrelated healthy volunteers (131 men, 231 
women), all self-reported as Spanish of Caucasian descent, with ages ranging 
from 19 to 30 years were included in this study following informed consent. All 
participants were questioned about previous diseases, type and amount of 
alcohol ingested, smoking habits and consumption of drugs. Table 1 
summarizes such information. Subjects with present or previous hepatic 
disease were excluded. Subjects taking any drug, including oral contraceptives, 
2 weeks prior to the administration of metamizole were also excluded. The 
inclusion of healthy individuals with Caucasian descent only, as well as the 
narrow age range, was intended to minimize the effect of potential confounders 
related to liver disorders, ethnicity or age. The protocol of this study was 
approved by the ethics committee of the University of Extremadura, Badajoz, 
Spain. 
Analysis of metamizole and metabolites in urine. 
After overnight fasting to avoid absorption variability [16] the participants were 
instructed to empty their bladders, and thereafter metamizole magnesium salt 
(Nolotil, Europharma S.A., Madrid, Spain) was administered as a single oral 
dose of 575 mg. Total urine was collected during 24h thereafter according 
previously described procedures [13-14]. Urine aliquots (20 mL) were stored in 
sterile plastic containers at - 80°C until analysis. Urine (1 mL) was alkalinized, 
and metamizole and its metabolites were chloroform-extracted. The organic 
phase was evaporated to dryness under a nitrogen stream. The residues were 
reconstituted in 500 µL mobile phase, and 20 µL aliquots were analyzed by 
HPLC. A Spherisorb ODS 5 µm particle size column (250 X 4.6 mm; Sugelabor, 
Madrid, Spain) was used. The mobile phase was water: methanol: 
triethylamine: acetic acid (70.9: 27.7: 0.9: 0.5), and the flow rate was 1 mL/min. 
Column effluents were monitored at 254 nm. Details of these procedures are 
described elsewhere [14]. Pure samples of methyl aminoantipyrine (MAA), 
formyl aminoantipyrine (FAA), acetyl aminoantipyrine (AAA), aminoantipyrine 
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(AA), and the internal standard isopropyl aminoantipyrine were kindly provided 
by Drs Bremer and Eekert (Hoesehst Aktiengesellsehaft, Radiochemistry 
Laboratory, D-6230 Frankfurt am Main 80, Germany). The metabolic ratios were 
calculated on the basis of the molar ratios by dividing the amount of metabolites 
by the amount of unchanged drug or metabolite, as follows: N-demethylation 
(AA+AAA/MAA); Formylation: FAA/MAA; Acetylation: AAA/AA. Additional ratios 
for these three reactions were calculated by dividing the amount of metabolites 
corresponding to each metabolic step by the amount of all the remaining 
metabolites. 
Identification of new metabolites: Ultra Performance Liquid Chromatography 
(UPLC) was carried out on an ACQUITY UPLC system (Waters Corp.) with a 
conditioned autosampler at 4 °C. The separation was accomplished on an 
ACQUITY UPLC BEH C18 column (50 mm × 2.1 mm i.d., 1.7 µm), which was 
maintained at 40 °C. The analysis was performed using methanol and water (50 
:50 v/v containing 0.01% formic acid) as the mobile phase with a flow rate of 0.5 
mL/min and an injection volume of 3µL. The Waters ACQUITY™ XevoQToF 
Spectrometer (Waters Corp.) was connected to the UPLC system via an 
electrospray ionization interface. This source was operated in positive ionization 
mode at 100 °C with the capillary voltage at 3.0 kV and a temperature of 
desolvation of 300 °C. The cone and desolvation gas flows were 40 and 800 
L/h, respectively. The collision gas flow applied was 0.2 mL / min. All data 
collected in Centroid mode were acquired using Masslynx™ software (Waters 
Corp.). Leucine-enkephalin was used at a concentration of 250pg/µL as the lock 
mass generating an [M+H]+ ion (m/z 556.2771) and fragment at m/z 120.0813 
with a flow rate of 50 µL/min to ensure accuracy during the MS analysis.  
Genotyping study. 
Genomic DNA was obtained from peripheral leukocytes and purified according 
to standard procedures. The target SNPs were selected according functional 
impact and allele frequency in the population studied. We analyzed the SNPs 
which constitute the signature for the alleles CYP2C8*3 (rs11572080), 
CYP2C8*4 (rs1058930), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), 
CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 
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(rs12248560), NAT2*5 (rs1801280), NAT2*6 (rs1799930), NAT2*7 (rs1799931), 
NAT2*14 (rs1801279). All SNPs were tested by means of pre-designed 
TaqMan Assays (Life Sciences, Alcobendas, Madrid, Spain) designed to detect 
the above mentioned SNPs (see supplemental Table S1 for details). 
The detection was carried out by qPCR in an Eppendorf realplex thermocycler 
by using fluorescent probes. The amplification conditions were as follows: After 
a denaturation time of 10 min at 96uC, 45 cycles of 92uC 15 sec 60uC 90 sec 
were carried out and fluorescence was measured at the end of every cycle and 
at endpoint. All samples were determined by triplicate and genotypes were 
assigned both, by the gene identification software (RealPlex 2.0, Eppendorf) 
and by analysis of the reference cycle number for each fluorescence curve, 
calculated by the use of CalQPlex algorithm (Eppendorf). For technical 
validation purposes, the amplified fragments for twenty individuals carrying 
every genotype, when available, were sequenced. For some SNPs the number 
of individuals homozygous for the minor allele did not permit to sequence 
twenty individuals (see below) and in such cases the amplified fragments 
corresponding to all homozygous individuals identified were sequenced.  
Statistical analyses 
A test for normality was applied to examine whether the continuous variables 
were normally distributed (see supplemental Table S2). When values were 
dichotomic (gender, drinking, smoking) the intergroup comparisons were 
performed by means of the two-tailed Student's t-test, except when the ratios 
studied had a non-normal distribution. For the rest of non-genetic comparisons, 
the non-parametric Spearman’s correlation was used. The variables with a p 
value < 0.1 in the univariate analysis were included in a multivariate analysis 
based on a logistic regression model by exact methods (maximum likelihood 
tests) to identify which were independently related to the result. To test the 
association of genotypes with the metabolic recoveries we used the non-
parametric K test. The statistical analysis was carried out by using the statistical 
software SPSS 17.0 for Windows (SPSS Inc. Chicago, Illinois, USA). Putative 
departures of Hardy-Weinberg equilibrium were calculated by using the 
software Haploview 4.2. Phenotype inference based on genetic analyses was 
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carried out according to standard procedures, assuming as loss of function or 
slow alleles CYP2C8*3, CYP2C8*4, CYP2C9*2, CYP2C9*3, CYP2C19*2, 
CYP2C19*3, NAT2*5, NAT2*6, NAT2*7 and NAT2*14, and as gain of function 
or rapid the allele CYP2C19*17. For recent reviews on phenotype inference, 
see [17-18]. According to standard procedures, a functional phenotype was 
inferred in the absence of these variant alleles. Haplotype reconstruction was 
carried out separately for CYP2C and for NAT2 alleles as follows: All possible 
haplotypes combining the SNPs analyzed in this study were constructed by 
using PHASE [19]. The reconstructed haplotypes were used for the analyses of 
the putative effect of haplotypes on metamizole metabolic profile. In addition, 
phased NAT2 haplotypes were used for phenotype inference in combination 
with the NAT2 haplotype table described elsewhere [20]. 
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RESULTS 
The four major metamizole metabolites were detected in the urine of all the 
subjects studied, albeit with a high interindividual variability. The major 
metabolite recovered was AAA, followed by FAA, MAA and AA, and no 
unchanged metamizole was detected in agreement with previous studies [9, 11, 
13-15, 21-23]. Table 2 shows the influence of non-genetic factors on the 
metamizole metabolic profile. Gender was significantly related to the acetylation 
capacity, with women showing about 20% higher AAA concentration and about 
40% higher acetylation ratio (AAA/AA) than men. The recoveries of the rest of 
major metabolites and the rest of metabolic ratios did not significantly differ 
between women and men. A statistically significant correlation of age with the 
recovery of the metabolites MAA and FAA, as well as the FAA/MAA ratio was 
observed (Table 2), with older individuals showing higher recovery of MAA, 
lower recovery of FAA and lower FAA/MAA ratio. Other parameters such as 
height, weight, body mass index, urine volume in 24 hours displayed statistically 
significant associations with the recovery of AA and AAA, as well as the ratio 
AAA/AA. However, this association may be due to the strong association of 
gender with the rest of the parameters (supplemental information Table S3 
shows such association). Smoking was statistically associated with an increase 
of roughly 40% in the demethylation ratio as well as a decrease of roughly 20% 
in the recovery of MAA and FAA among smokers as compared to non-smokers 
(Table 2). In addition, the analysis of the bivariate correlation of the number of 
cigarettes per day was related to the increase in the demethylation ratio, and to 
a decrease in the recovery of FAA (see Table 2). Drinking habits were 
associated with a significant decrease in the acetylation ratio of about 30%, and 
with a significant increase of about 20% in the recovery of AA. In addition, the 
number of drinks per week inversely correlated with the acetylation ratio (Table 
2). Because many of the previously mentioned non-genetic factors are 
associated (see supplemental table S3), we performed multivariate analyses to 
elucidate which factors are actually associated with the recovery of major 
metamizole metabolites and with the metabolic ratios by using multiple 
regression. These analyses confirmed the influence of gender in the acetylation 
ratio (p = 0.005), the influence of age in the formylation ratio (p = 0.001), as well 
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as the inverse correlation of the number of drinks per week in the recovery of 
AAA (p<0.001). The rest of putative associations were discarded in the 
multivariate analysis.  
Because it has been previously shown that the acetylation ratio is strongly 
related to NAT2 polymorphisms [24], we analyzed the inferred NAT2 genotypes 
according to gender and the results indicate similar frequencies in women and 
men, for slow, intermediate and rapid acetylator inferred phenotypes (see 
supplemental information Table S4), thus indicating that the gender-related 
differences observed in the acetylation ratio are independent of NAT2 
polymorphisms. 
The SNP frequencies observed in the study group are consistent with those 
previously described in healthy Spaniards subjects [20, 25-29] and are at 
Hardy-Weinberg’s equilibrium (see supplemental information Table S5). Table 3 
shows the effect of inferred phenotypes on the major metamizole metabolites 
and metabolic ratios. Details about the influence of every SNP are summarized 
in supplemental information Table S6. Common functional CYP2C8 
polymorphisms did not show any influence in the recoveries of metamizole 
metabolites or in the metabolic ratios. The inferred CYP2C9 phenotype was 
related to a nearly-significant decrease of the formylated metabolite, as well as 
a significant decrease in the formylation ratio, among carriers of loss-of function 
CYP2C9 alleles. Most of this effect is attributable to the variant allele 
CYP2C9*3, whereas the presence of CYP2C9*2 was related to a weaker effect 
(see supplemental information Table S6), which is consistent with the weaker 
impairment in drug metabolism in vivo caused by CYP2C9*2 as compared to 
CYP2C9*3 [17, 30-31]. 
CYP2C19  loss of function alleles markedly influenced the demethylation ratio 
as shown in Table 3. The reduction in the demethylation ratio is consistent with 
a reduction in the recovery of downstream metabolites AA and AAA among 
slow CYP2C19 metabolizers. This effect is due to the CYP2C19*2 allele since 
no carriers of the loss of function CYP2C19*3 alleles were identified in the study 
group. The gain-of-function CYP2C19*17 allele did not significantly increase the 
demethylation ratio or the concentration of downstream metabolites. 
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Because CYP2C SNPs are frequently at linkage disequilibrium [17], CYP2C 
haplotypes were reconstructed from genotyping data. The commonest 
haplotype was that lacking functional SNPs at the CYP2C9 locus, with a 
frequency of 45.7% (see supplemental information Figure S7). When 
participants were stratified according such haplotypes, correlation with 
metamizole metabolite recoveries and metabolic ratios was lower than that 
obtained by using phenotype inference (see supplemental information Table 
S8). This indicates that, for metamizole metabolism, CYP2C haplotype analyses 
do not improve the phenotype inference obtained by genotyping because the 
most of the association is due to the CYP2C19 gene only. 
The inferred slow NAT2 phenotype is strongly associated with a decrease in the 
acetylation ratio and in the recovery of AAA (Table 3). This effect is associated 
to all NAT2 loss of function alleles analyzed (see supplemental information 
Table S6). Interestingly, the decrease in the acetylation ratio is accompanied by 
a significant increase of the recovery of the upstream metabolite MAA. Slow 
acetylator individuals show almost double concentrations of MAA and less than 
half of the concentrations of AAA as compared to non carriers of loss of function 
NAT2 alleles, in agreement with previous reports [32]. The increase in MAA 
concentration is likely to underlie the association of the inferred slow NAT2 
phenotype with significantly lower ratios in the metabolic steps related to MAA 
(formylation and demethylation) shown in Table 3, because the recoveries of 
FAA and AA are not significantly affected by the inferred NAT2 phenotype. 
Because a differential functional effect in vivo of NAT2 loss of function alleles 
has been described by using caffeine as a substrate [33], we tested whether 
such differential effect was observed on the acetylation of AA. The comparison 
of the recoveries of MAA, AAA and the acetylation ratio between carriers of 
NAT2*5 and NAT2*6 in heterozygosity and in homozygosity is shown in 
supplemental Table S9. Individuals who were homozygous for the NAT2*6 
allele displayed a significantly lower AAA recovery and lower acetylation ratio as 
compared to individuals homozygous for the NAT2*5 allele, thus indicating a 
differential effect of these variant alleles, which is consistent with that reported 
with caffeine [33]. The differential effect of NAT2*7 could not be disclosed 
because only two individuals carried the NAT2*7 allele in combination with 
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NAT2*4 and no homozygous individuals for NAT2*7 were identified in the study 
group. 
In order to identify additional metamizole metabolites, we analyzed a subgroup 
of 55 participants selected according their genotypes. HPLC-mass spectrometry 
analyses revealed the presence of two additional metabolites, namely 
arachidonoyl (N)-methylamide (designated as ARA-NMA) and arachidonoyl 
methylamide (ARA-MA). Besides these, no additional metabolites were 
identified. The mean ± SD recoveries were 0.68 ± 1.17 mg and 1.03 ± 2.20 mg, 
respectively. However, large interindividual variability was observed, with some 
individuals displaying high concentrations. The maximum recovery among the 
55 individuals analyzed was equal to 7.23 mg for ARA-NMA and 12.93 mg for 
ARA-MA. The occurrence of these arachidonoyl amides have been previously 
reported to occur in mice, and it has been shown that these metabolites have 
pharmacological activity [34]. The recoveries of both ARA-NMA and ARA-MA 
strongly correlated with the recovery of the precursor MAA (p< 0.001) and ARA-
MA correlated with FAA at lesser extent (p = 0.014) (see supplemental Table 
S10). In addition the recovery of ARA-NMA strongly correlated with initial 
metabolic ratios (formylation and demethylation; p = 0.002 and p =< 0.001, 
respectively) whereas the correlation with the acetylation ratio was weaker (p = 
0.028). The recovery of ARA-MA correlated with the formylation (p = 0.001) and 
demethylation ratios (p < 0.001), but the correlation of ARA-MA with the 
acetylation ratio did not reach statistical significance (p = 0.053). Women 
displayed about 40% higher mean concentrations of both arachidonoyl 
metabolites as compared to men, although the differences were not statistically 
significant in the univariate analysis. The non-genetic factor with the strongest 
association to the recovery of arachidonoyl metabolites was drinking with 
concentrations of ARA-NMA being 70% higher (p = 0.039) and concentrations 
of ARA-MA being over twice (p = 0.001) in drinkers as compared to non-
drinkers. However, no correlation was observed with the number of drinks per 
week. Supplemental Table S11 summarizes all comparisons. Multivariate 
analyses confirmed the influence of gender (p = 0.002) and height (p = 0.012) in 
the recovery of ARA-NMA. Similar associations for gender (p = 0.016) and 
height (p = 0.007) in the recovery of ARA-MA were observed, whereas the rest 
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of non-genetic factors were discarded in the multiple comparison analysis. 
Putative associations of arachidonoyl metabolites with other phenotypic 
parameters as observed in the univariate analyses (see supplemental Table 
S11) are likely to be due to the strong association of gender with the rest of the 
parameters (supplemental information Table S3 shows such association). 
Regarding genetic factors, Table 4 shows that, besides a weak effect of the 
CYP2C9 genotype in the recovery of ARA-NMA, individuals who were 
homozygous for the gain of function CYP2C19*17 allele display a marked 
reduction in the recovery of both arachidonoyl metabolites as compared with 
individuals with non-mutated CYP2C19 genes. By turn, individuals homozygous 
for NAT2 slow alleles show the highest mean concentration for both 
arachidonoyl metabolites. For both genotypes (CYP2C19 and NAT2) a gene-
dose effect on the recovery of both metamizole metabolites can be observed 
(Table 4). 
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DISCUSSION 
Metamizole is a commonly used analgesic which is prescribed or used over-the-
counter use in many countries. This, together with the severity of some of the 
adverse reactions secondary to the use of metamizole justifies studies focusing 
on factors underlying the variability of metamizole biotransformation. The 
understanding of factors modifying metamizole biodisposition is surprisingly low. 
The association of metamizole acetylation with the acetylator phenotype and 
genotype is well known [10-11, 32, 35-36]. In contrast, little is known about the 
enzymes involved in the initial (oxidative) metamizole biodisposition in vivo. 
These enzymes have not been identified in man, although in vitro evidences 
supports a role for CYP2C19 and other CYP enzymes in the N-demethylation of 
aminopyrine, a closely related compound that follows the same metabolic route 
[37]. The enzyme involved in the formylation of MAA remains unknown, but It 
has been shown that the metabolic ratios of MAA demethylation and formylation 
in vivo strongly correlate between themselves [36]. The influence of CYP2C19 
and other gene variants on the oxidative biotransformation of metamizole in vivo 
remains to be elucidated. This study is aimed to elucidate the putative role of 
polymorphic drug metabolism as well as phenotypic factors in metamizole 
metabolism in vivo. 
It is well known that the main pharmacological effects of metamizole are due to 
the primary metabolite MAA. After the oral administration of 500 mg dipyrone, 
MAA plasma concentration is above the IC50 concentration for the inhibition of 
COX-1 and COX-2 for over 8 hours, whereas the less potent metabolite AA 
does not reach the IC50 values even after the administration of 1000 mg  [3]. 
For that reason, it is likely that impairment in the oxidative metabolism of 
metamizole would be related to adverse drug reactions. Hence it is surprising 
that the only metabolic polymorphism that has been studied with regard to 
metamizole adverse drug reactions is the acetylation polymorphism [12]. 
In this study, we have identified phenotypic (gender, age or drinking habits) and 
genotype (CYP2C9, CYP2C19 and NAT2) factors that modify metamizole 
metabolic profiles. This is the first study that identified genetic factors related to 
oxidative metamizole metabolism in vivo. Our findings support a relevant role 
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for the CYP2C19 and CYP2C9 enzymes and confirm that functional 
polymorphisms affecting the CYP2C19 gene modify the N-demethylation and 
formylation pathways in agreement with in vitro evidences [37]. Our findings 
confirm that the acetylation of AA is more efficient in women, in non-drinkers 
and in carriers of non-mutated NAT2 alleles, with a differential effect of NAT2*5 
and NAT2*6 alleles consistent with that described with other NAT2 substrate 
[33]. A gene-dose effect is present for all genetic associations identified in this 
study. 
We did not identify oxalic acid derivatives previously described [2]. By turn, we 
identified for the first time in man the occurrence of arachidonoyl amides. The 
recoveries of these metabolites are higher in women and are related to 
CYP2C9, CYP2C19 and NAT2 polymorphisms. The presence of the rapid 
CYP2C19*17 allele is related to a low recovery of arachidonoyl amides. In 
addition, our findings suggest that the NAT2 slow acetylator status drives the 
metabolism towards arachidonoyl amides, which is an unexpected finding. 
Because the concentrations of these amides strongly correlate with MAA 
(supplemental Table S10) and because the NAT2 status strongly correlated 
with the recovery of MAA (Table 3), it is likely that the observed association of 
slow NAT2 genotypes and higher production of arachidonoyl amides, as well as 
a lower N-demethylation or formylation ratios, would be related to an increased 
availability of the precursor metabolite MAA. Both arachidonoyl amides inhibit 
COX enzymes and both binds to cannabinoid CB1 and CB2 receptors with Ki 
values in the low micromolar concentration (between 3 and 8 µM) [34]. It is 
particularly interesting that the arachidonoyl amide designated as ARA-NMA is 
nearly 2.7 fold more potent inhibitor of the enzyme COX1 and 4.4 fold more 
potent inhibitor of COX2, as compared with MAA, which is considered the active 
metabolite of metamizole [34]. Taking into consideration the recovered 
concentration of MAA and ARA-NMA and their relative potencies for inhibiting 
the COX enzymes, in some individuals analyzed, particularly in women with the 
slow acetylation genotype, the contribution of these metabolites to COX 
inhibition is expected to have a similar extent.  
In summary, we identified genetic and non-genetic factors that cosegregate with 
metamizole metabolic profiles, most of these factors being related to increased 
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recovery of the active metabolite MAA. These factors (summarized on 
supplemental Figure S12) could be tested as putative biomarkers for drug 
response and for the risk of developing adverse reactions after metamizole use 
(for instance for the assessment of hypersensibility reactions when no challenge 
is recommended due to the risk of anaphylaxis). Morevover, toxic 
photoproducts of MAA have been described, whereas FAA and AAA showed 
slower photodegradation kinetics [38]. This raises the hypothesis that 
individuals with genotypes or phenotype factors leading to increased MAA 
concentrations may be at higher risk of developing toxic reactions related to 
metamizole and, once relevant factors are disclosed (this study) further studies 
are required to elucidate the role of these factors in adverse reactions. In 
addition, we identified two pharmacologically active arachidonoyl metabolites, 
and we assessed genetic and non-genetic factors that are related with the 
production of these metabolites. Due to their pharmacological potency, further 
studies on the role of these arachidonoyl metabolites in drug response and in 
the risk of developing adverse effects are warranted. 
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Table 1. Characteristics of the participants (n=362). 
 
Men (n; %) 131 (36.2%)   
Women (n, %) 231 (63.8%)   
Age, years (mean ± SD; range) 21.09 ± 2.06 (19-36)   
Weight, kg. (mean ± SD; range) 63.7 ± 12.36 (42.6-115.0)   
Height, cm. (mean ± SD; range) 168.59 ± 8.59 (152-191)   
Body mass index (mean ± SD; range) 22.28 ± 3.11 (16.64-35.16)   
Urine volume, mL. (mean ± SD; range) 1289.72 ± 538.34 (450-4200)   
Non-drinkers (n, %) 216 (59.7%)   
Drinkers (n, %) 146 (40.3%) Drinks per week (mean ± SD; range) 5.46 ± 3.13 (1-14) 
Non-smokers. (n, %) 275 (76.2%)   
Smokers (n, %) 86 (23.8%) Cigarettes per day (mean ± SD; range) 8.61 ± 6.47 (1-25) 
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Table 2. Effect of non-genetic factors on major metamizole metabolite recoveries and metabolic ratios. 
 
 MAA (mg) Intergroup 
comparison 
values 
FAA (mg) Intergroup 
comparison 
values 
AA (mg) Intergroup 
comparison 
values 
AAA (mg) Intergroup 
comparison 
values 
Formylation 
ratio 
(FAA/MAA) 
Intergroup 
comparison 
values 
Demethylatio
n ratio  
((AA+AAA)/M
AA)) 
Intergroup 
comparison 
values 
Acetylation 
ratio 
(AAA/AA) 
Intergr
compar
value
Men (n= 131) 10.18 ± 4.98 p = 0.532  45.03 ± 18.09 p = 0.248 10.90 ± 5.58 p = 0.086  63.73 ± 45.25 p < 0.001  5.51 ± 3.29 p =0.065  10.25 ± 9.24 p = 0.162  7.07 ± 5.36 p < 0.00
Women (n = 
231) 11.01 ± 6.26  42.71 ± 18.02  10.60 ± 8.39  76.02 ± 39.49  4.91 ± 2.98  10.91 ± 9.05  10.14 ± 8.21  
Age  p = 0.016  p = 0.005  p = 0.090  p = 0.178  p < 0.001  p = 0.103  p = 0.01
Weight  p = 0.641  p = 0.762  p = 0.639  p = 0.041  p = 0.414  p = 0.437  p = 0.11
Height  p = 0.657  p = 0.308  p = 0.671  p = 0.003  p = 0.076  p = 0.234  p = 0.01
Body mass 
index  p = 0.884  p = 0.440  p = 0.935  p = 0.059  p = 0.458  p = 0.205  p = 0.32
Urine volume 
(ml)  p = 0.767  p = 0.393  p = 0.001  p = 0.065  p = 0.943  p = 0.665  p = 0.00
Drinkers 10.20 ± 5.22 p = 0.999 42.58 ± 19.13 p = 0.466 11.91 ± 9.22 p = 0.037 67.34 ± 38.83 p = 0.111 5.12 ± 2.82 p = 0.888 10.62 ± 8.74 p = 0.671 7.18 ± 4.89 p = 0.00
Non-drinkers 10.57 ± 6.08  44.42 ± 17.22  9.89 ± 6.01  73.75 ± 42.33  5.33 ± 3.36  10.97 ± 9.73  10.42 ± 8.90  
Drinks per 
week  p = 0.516  p = 0.037  p = 0.043  p < 0.001  p = 0.744  p = 0.298  p < 0.00
Smokers 8.85 ± 5.48 p = 0.013 36.46± 18.83 p = 0.007 12.70 ± 7.67 p = 0.056 77.77 ± 40.39 p = 0.134 5.37 ± 2.90 p = 0.616 14.72 ± 10.04 p = 0.001 8.51± 6.58 p = 0.55
Non-smokers 10.68 ± 5.75  44.78± 17.66  10.46 ± 7.55  70.02 ± 40.93  5.21 ± 3.18  10.19 ± 9.04  9.11 ± 7.76  
Cigarettes per 
day   p = 0.077  p = 0.022  p = 0.199  p = 0.260  p = 0.750  p = 0.017  p = 0.86
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Table 3. Effect of genetic factors on major metamizole metabolite recoveries and metabolic ratios. 
 
 MAA (mg) Intergroup 
comparison 
values 
FAA (mg) Intergroup 
comparison 
values 
AA (mg) Intergroup 
comparison 
values 
AAA (mg) Intergroup 
comparison 
values 
Formylati
on ratio 
(FAA/MA
A) 
Intergroup 
comparison 
values 
Demethyl
ation ratio  
((AA+AAA
)/MAA)) 
Intergroup 
comparison 
values 
Acetylatio
n ratio 
(AAA/AA) 
Intergroup 
comparison 
values 
CYP2C8*1/*1 10.92 ± 6.22  
43.31 ± 
19.43  
10.81 ± 
8.06  
70.29 ± 
45.66  
5.09 ± 
3.04  
10.68 ± 
9.15  
8.70 ± 
7.32  
CYP2C8*1/ 
slow 
10.63 ± 
5.37 p = 0.927 
43.71 ± 
15.33 p = 0.828 
10.43 ± 
6.67 p = 0.551 
69.80 ± 
34.39 p = 0.547 
5.18 ± 
3.30 p = 0.877 
10.49 ± 
9.31 p = 0.710 
9.56 ± 
8.06 p = 0.174 
CYP2C8 
slow/slow 
9.77 ± 
3.53  
41.99 ± 
22.00  
9.52 ± 
6.87  
83.99 ± 
45.57  
4.86 ± 
3.06  
11.08 ± 
7.68  
10.48 ± 
5.87  
CYP2C9*1/*1 10.82 ± 6.34  
44.86 ± 
19.17  
10.46 ± 
5.79  
69.59 ± 
44.42  
5.39 ± 
3.36  
10.70 ± 
9.50  
8.50 ± 
7.19  
CYP2C9*1/ 
slow 
10.67 ± 
5.10 p = 0.715 
41.87 ± 
16.43 p = 0.055 
10.58 ± 
8.60 p = 0.568 
73.61± 
38.49 p = 0.123 
4.84 ± 
2.68 p = 0.011 
10.84 ± 
8.69 p = 0.264 
10.20 ± 
8.10 p = 0.101 
CYP2C9 
slow/slow 
11.42 ± 
5.02  
35.48± 
17.12  
13.655 ± 
16.22  
63.33± 
43.33  
3.34 ± 
1.66  
7.94 ± 
6.75  
7.38 ± 
6.12  
CYP2C19*1/*
1 
10.32 ± 
5.67  
43.06 ± 
18.74  
10.89 ± 
6.69  
74.21 
±46.80  
5.35 ± 
3.33  
11.96 ± 
8.06  
8.78 ± 
6.50  
CYP2C19*1/ 
slow 
11.55 ± 
6.21 p = 0.056 
46.28 ± 
18.61 p = 0.317 
10.46 ± 
5.87 p = 0.474 
65.40 ± 
35.57 p = 0.132 
4.80 ± 
2.70 p = 0.048 
8.05 ± 
5.81 p = 0.001 
8.50 ± 
7.80 p = 0.785 
CYP2C19 
slow/slow 
10.01 ± 
0.15  
37.10 ± 
15.11  
6.97 ± 
5.76  
39.72 ± 
9.53  
2.64 ± 
1.07  
3.33 ± 
0.81  
9.82 ± 
7.28  
CYP2C19*1/ 
rapid 
10.81 ± 
6.39 
 
p = 0.233 
42.89 ± 
17.83 
 
p = 0.332 
10.54 ± 
10.32 
 
p = 0.261 
66.75 ± 
39.58 
 
p = 0.456 
5.20 ± 
3.10 
 
p = 0.038 
10.54 ± 
9.32 
 
p = 0.164 
9.80 ± 
9.31 
 
p = 0.938 
CYP2C19 
rapid/rapid 
11.90 ± 
3.88  
36.18 ± 
12.73  
9.71 ± 
5.62  
69.46 ± 
37.98  
3.34 ± 
1.76  
7.65 ± 
4.72  
8.99 ± 
6.45  
NAT2*4/*4 6.71  ± 3.02  
48.80  ± 
20.38  
9.91  ± 
4.37  
123.90  ± 
30.52  
8.18  ± 
3.30  
22.13  ± 
7.87  
16.02  ± 
10.12  
NAT2*4/slow 8.87  ± 4.78 p = 0.001 
42.14  ± 
18.44 p = 0.335 
11.36  ± 
7.32 p = 0.558 
91.66  ± 
46.26 p = 0.001 
6.28  ± 
3.74 p = 0.001 
15.81  ± 
9.92 p = 0.001 
10.85  ± 
7.87 p = 0.001 
NAT2 
slow/slow 
12.82  ± 
6.15  
43.56  ± 
17.81  
10.22  ± 
8.12  
47.050 ± 
19.29  
3.77  ± 
1.45  
5.02  ± 
2.02  
6.64  ± 
5.54  
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CYP2C8 slow include CYP2C8*3 and *4; CYP2C9 slow include CYP2C9*2 and *3; CYP2C19 slow include CYP2C19*2 and *3; CYP2C19 rapid include 
CYP2C19*17; NAT2 slow include NAT2*5, *6, *7 and *14. 
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Table 4. Effect of genetic factors on araquidonate metabolites recoveries. 
 
 ARA-NMA (mg) Intergroup comparison 
values ARA-MA (mg) 
Intergroup comparison 
values 
CYP2C8*1/*1 
n = 36 0.75 ± 1.34 reference 1.06 ± 2.26 reference 
CYP2C8*1/ slow 
n = 10 0.79 ± 1.01 p = 0.938 1.66 ± 2.82 p = 0.271 
CYP2C8 slow/ slow 
n = 8 0.15 ± 0.09 p = 0.086 0.75 ± 0.06 p = 0.108 
CYP2C9*1/*1 
n = 37 0.81 ± 1.34 reference 1.29 ± 2.57 reference 
CYP2C9*1/ slow 
n = 10 0.24 ± 0.13 p = 0.040 0.33 ± 0.41 p = 0.091 
CYP2C9 slow/ slow 
n = 8 0.59 ± 1.03 p = 0.706 0.66 ± 1.39 p = 0.434 
CYP2C19*1/*1 
n = 21 0.94 ± 1.65 reference 1.69 ± 3.34 reference 
CYP2C19*1/ slow 
n = 6 1.16 ± 0.94 p = 0.533 1.32 ± 0.94 p = 0.164 
CYP2C19 slow/slow 
n = 3 0.26 ± 0.10 p = 0.208 0.27 ± 0.07 p = 0.154 
CYP2C19*1/ rapid 
n = 14 0.50 ± 0.86 p = 0.123 0.67 ± 1.04 p = 0.028 
CYP2C19 slow/rapid 
n = 2 0.32 ± 0.21 p = 0.340 0.30 ± 0.02 p = 0.234 
CYP2C19 rapid/rapid 
n = 9 0.24 ± 0.14 p = 0.037 0.25 ± 0.18 p = 0.020 
NAT2*4/*4 
n=8 0.12 ± 0.08 reference 0.10 ± 0.06 reference 
NAT2*4/slow 
n = 17 0.46  ± 0.69 p = 0.075 0.55 ± 0.77 p = 0.022 
NAT2 slow/slow 
n = 30 0.94  ± 1.45 p= 0.045 1.54  ± 2.83 p = 0.039 
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CYP2C8 slow include CYP2C8*3 and *4; CYP2C9 slow include CYP2C9*2 and *3; CYP2C19 slow include CYP2C19*2 and *3; CYP2C19 rapid include 
CYP2C19*17; NAT2 slow include NAT2*5, *6, *7 and *14. 
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Supplemental table S1. Genotyping assays used in this study. 
 
Gene Allele 
signature 
rs number chromosomal location Functional effect Assay identification 
CYP2C8 CYP2C8*3 rs11572080 10:96827030 Decreased metabolism C__25625794_10 
 CYP2C8*4 rs1058930 10:96818119 Decreased metabolism C__25761568_20 
CYP2C9 CYP2C9*2 rs1799853 10:96702047 Decreased metabolism C__25625805_10 
 CYP2C9*3 rs1057910 10:96741053 Decreased metabolism C__27104892_10 
CYP2C19 CYP2C19*2 rs4244285 10:96541616 Decreased metabolism C__25986767_70 
 CYP2C19*3 rs4986893 10:96540410 Decreased metabolism C__27861809_10 
 CYP2C19*17 rs12248560 10:96521657 Increased expression C____469857_10 
NAT2 NAT2*5 rs1801280 8:18257854 Decreased metabolism C___1204093_20 
 NAT2*6 rs1799930 8:18258103 Decreased metabolism C___1204091_10 
 NAT2*7 rs1799931 8:18258370 Decreased metabolism C____572770_20 
 NAT2*14 rs1801279 8:18257704 Decreased metabolism C____572771_10 
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Supplemental table S2. Normality test for the phenotypic characteristics analyzed in this study: 
 
Characteristic Z (Kolmogorov-
Smirnov) 
P value 
Age 5.72 <0.001 
Weight 2.50 <0.001 
Height 1.81 =0.003 
Body mass index 1.41 =0.038 
Urine volume (24 hours) 2.34 <0.001 
Drinks per week 5.98 <0.001 
Smoker/Non smoker 9.56 <0.001 
FAA (mg) 0.76 =0.618 
AAA (mg) 2.71 <0.001 
AA (mg) 2.24 <0.001 
MAA (mg) 1.77 =0.004 
ARA-NMA (mg) 2.32 <0.001 
ARA-MA (mg) 2.40 <0.001 
Recovery (percent of dose) 1.17 =0.127 
Formylation ratio 1 (FAA/MAA) 2.73 <0.001 
Formylation ratio 2 (FAA/(MAA+AA+AAA)) 1.55 =0.017 
Demethylation ratio 1 ((AA+AAA)/MAA)) 3.65 <0.001 
Demethylation ratio 2 ((AA+AAA)/(MAA+FAA)) 2.48 <0.001 
Acetylation ratio 1 (AAA/AA) 2.87 <0.001 
Acetylation ratio 2 ((AAA/(AA+MAA+FAA) 2.60 <0.001 
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Supplemental table S3: Association between non-genetic factors. 
 
 Age Weight Height Body 
Mass 
Index 
Urine 
volume 
Drinker 
(yes/no) 
Drinks 
per 
week 
Smoker 
(yes/no) 
Cigarett
es per 
day 
Gender 
(men/women) 
p = 0.005 p < 0.001 p < 0.001 p <0.001 p = 0.001 p < 0.001 p < 0.001 p= 0.470 p = 0.720 
Age  p = 0.001 p = 0.001 p = 0.041 p = 0.519 p = 0.467 p = 0.194 p = 0.235 p = 0.588 
Weight   p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.401 p = 0.958 
Height    p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.252 p = 0.731 
Body Mass 
Index 
    p < 0.001 p = 0.013 p = 0.004 p = 0.774 p = 0.912 
Urine volume      p = 0.053 p = 0.032 p = 0.011 p = 0.064 
Drinker 
(yes/no) 
      p < 0.001 p < 0.001 p < 0.001 
Drinks per 
week 
       p < 0.001 p < 0.001 
Smoker 
(yes/no) 
        p < 0.001 
 
The significance values for bilateral Spearman correlations are shown. 
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Supplemental table S4: NAT2 SNPs and inferred acetylation phenotype by gender. 
 
SNP  identifier Men, No. (%; 95 % CI) Women, No. (%; 95 % CI) Intergroup comparison values 
rs1801280 (NAT2*5) 
 
 
 
T/T 45 (34.4; 26.2-42.5) 85 (36.8; 30.6-43.0)  
T/C 70 (53.4; 44.9-62.0) 105 (45.5; 39.0-51.9) Chi-square = 2.88; p = 0.238 
C/C 16 (12.2; 6.6-17.8) 41 (17.7; 12.8-22.7)  
rs1799930 (NAT2*6) 
 
 
 
G/G 55 (42.0; 33.5-50.4) 103 (44.6; 38.2-51.0)  
G/A 62 (47.3; 38.8-55.9) 105 (45.5; 39.0-51.9) Chi-square = 0.24; p = 0.888 
A/A 14 (10.7; 5.4-16.0) 23 (10.0; 6.1-13.8)  
rs1799931 (NAT2*7) 
 
 
 
G/G 126 (96.2; 92.9-99.5) 220 (95.2; 92.5-98.0)  
G/A 5 (3.8; 0.5-7.1) 11 (4.8; 2.0-7.5) Chi-square = 0.18; p = 0.674 
A/A 0 (0.0; 0.0-0.0) 0 (0.0; 0.0-0.0)  
Inferred acetylation phenotye 
 
 
 
Rapid 9 (6.9; 2.5-11.2) 18 (7.8; 4.3-11.2)  
Intermediate 54 (41.2; 32.8-49.7) 92 (39.8; 33.5-46.1) Chi-square = 0.14; p = 0.932 
Slow 68 (51.9; 43.4-60.5) 121 (52.4; 45.9-58.8)  
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Supplemental Table S5. SNP frequencies observed in the present study. 
SNP  identifier No. (%; 95 % CI) Hardy-Weinberg’s  P (Pearson) 
rs11572080 (CYP2C8*3) 
  
C/C 269 (74.3; 69.8-78.8)  
C/T 84 (23.2; 18.9-27.6) p = 0.431 
T/T 9 (2.5; 0.9-4.1)  
rs1058930 (CYP2C8*4) 
  
G/G 324 (89.5; 86.3-92.7)  
G/C 35 (9.7; 6.6-12.7) p = 0.070 
C/C 3 (0.8; 0.-1-1.8)  
rs1799853 (CYP2C9*2) 
  
C/C 237 (65.5; 60.6-70.4)  
C/T 111 (30.7; 25.9-35.4) p = 0.824 
T/T 14 (3.9; 1.9-5.9)  
rs1057910 (CYP2C9*3) 
  
A/A 302 (83.4; 79.6-87.3)  
A/C 58 (16.0; 12.2-19.8) p = 0.660 
C/C 2 (0.6; 0.-2-1.3)  
rs4244285 (CYP2C19*2) 
  
G/G 274 (75.7; 71.3-80.1)  
G/A 81 (22.4; 18.1-26.7) p = 0.724 
A/A 7 (1.9; 0.5-3.4)  
rs4986893 (CYP2C19*3) 
  
G/G 362 (100.0; 100.0-100.0)  
G/A 0 (0.0; 0.0-0.0) -- 
A/A 0 (0.0; 0.0-0.0)  
rs12248560 (CYP2C19*17) 
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C/C 232 (64.1; 59.1-69.0)  
C/T 116 (32.0; 27.2-36.9) p = 0.916 
T/T 14 (3.9; 1.9-5.9)  
rs1801280 (NAT2*5) 
  
T/T 130 (35.9; 31.0-40.9)  
T/C 175 (48.3; 43.2-53.5) p = 0.881 
C/C 57 (15.7; 12.0-19.5)  
rs1799930 (NAT2*6) 
  
G/G 158 (43.6; 38.5-48.8)  
G/A 167 (46.1; 41.0-51.3) p = 0.462 
A/A 37 (10.2; 7.1-13.3)  
rs1799931 (NAT2*7) 
  
G/G 346 (95.6; 93.5-97.7)  
G/A 16 (4.4; 2.3-6.5) p = 0.667 
A/A 0 (0.0; 0.0-0.0)  
rs1801279 (NAT2*14)  
  
G/G 362 (100.0; 100.0-100.0)  
G/A 0 (0.0; 0.0-0.0) -- 
A/A 0 (0.0; 0.0-0.0)  
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Supplemental table S6: Effect of SNPs on major metamizole metabolite recoveries and metabolic ratios. 
 
 MAA (mg) Intergroup 
comparison 
values 
FAA (mg) Intergroup 
comparison 
values 
AA (mg) Intergroup 
comparison 
values 
AAA (mg) Intergroup 
comparison 
values 
Formylatio
n ratio 
(FAA/MAA
) 
Intergroup 
comparison 
values 
Demethyla
tion ratio  
((AA+AAA
)/MAA)) 
Intergroup 
comparison 
values 
Acetylatio
n ratio 
(AAA/AA) 
Intergroup 
comparison 
values 
CYP2C8*3 
 rs11572080 
C/C 
11.11 ± 
6.31 
 44.02 ± 
19.00 
 10.90 ± 
7.72 
 69.87 ± 
43.92 
 5.12 ± 3.07  10.49 ± 
8.99 
 8.48 ± 7.10   
CYP2C8*3 
 rs1157208 
C/T 
10.07 ± 
4.48 
p = 0.576 42.51 ± 
15.61 
p = 0.163 9.95 ± 7.13 p = 0.104 71.45 ± 
36.37 
p = 0.618 5.15 ± 3.29 p = 0.618 10.89 ± 
9.70 
p = 0.453 10.50 ± 
8.56 
p = 0.049 
CYP2C8*3 
 rs1157208 
T/T 
8.96 ± 3.56  33.74 ± 
19.52 
 9.71 ± 8.43  86.68 ± 
50.11 
 4.32 ± 2.90  11.91 ± 8.6  11.57 ± 
6.99 
 
CYP2C8*4 
rs1058930 
G/G 
10.62 ± 
5.77 
 42.88 ± 
18.58 
 10.59 ± 
7.85 
 71.22 ± 
43.62 
 5.10 ± 3.10  10.81 ± 
9.25 
 9.25 ± 7.70  
CYP2C8*4  
rs1058930 
G/C 
12.52 ± 
6.85 
p = 0.440 45.88 ± 
13.72 
p = 0.016 11.14 ± 
4.95 
p = 0.270 61.71 ± 
26.58 
p = 0.203 4.93 ± 3.25 p = 0.163 8.50 ± 7.71 p = 0.062 6.76 ± 5.05 p = 0.253 
CYP2C8*4  
rs1058930 
C/C 
9.66 ± 
12.52 
 71.09 ± 
1.33 
 11.56 ± 
0.91 
 104.00 ± 
32.37 
 7.98 ± 2.52  13.62 ± 
6.80 
 9.17 ± 3.37  
CYP2C9*2 
rs1799853 
C/C 
10.85 ± 
6.25 
 43.70 ± 
19.01 
 10.68 ± 
7.72 
 69.31 ± 
43.79 
 5.22 ± 3.22  10.66 ± 
9.23 
 8.64 ± 7.08  
CYP2C9*2 
rs1799853 
C/T 
10.81 ± 
4.61 
p = 0.439 43.48± 
15.65 
p = 0.131 10.60 ± 
7.06 
p = 0.619 74.17 ± 
36.14 
p = 0.436 4.81 ± 2.77 p = 0.391 10.36 ± 
8.83 
p = 0.699 10.16 ± 
8.71 
p = 0.347 
CYP2C9*2 
 rs1799853 
T/T 
8.84 ± 3.96  30.92 ± 
15.35 
 10.24 ± 
9.66 
 82.82 ± 
55.24 
 4.02 ± 2.41  11.74 ± 
8.93 
 11.25 ± 
7.84 
 
CYP2C9*3 
rs1057910   
A/A 
10.68 ± 
5.88 
 44.17 ± 
18.39 
 10.51 ± 
6.28 
 71.57 ± 
42.85 
 5.26 ± 3.22  10.79 ± 
9.36 
 9.09 ± 7.72  
CYP2C9*3 
rs1057910   
A/C 
11.54 ± 
5.94 
p = 0.550 40.26 ± 
17.07 
p = 0.040 11.34 ± 
9.56 
p = 0.336 67.05 ± 
40.33 
p = 0.529 4.41 ± 2.31 p = 0.027 9.80 ± 7.93 p = 0.899 8.96 ± 6.29 p = 0.055 
CYP2C9*3 
rs1057910   
C/C 
8.96  16.30  40.88  38.09  1.83  7.87  1.28  
CYP2C19*2 
rs4244285 
G/G 
10.51 ± 
5.83 
 42.70 ± 
18.20 
 10.72 ± 
8.12 
 71.29± 
44.07 
 5.22 ± 3.20  11.28 ± 
9.80 
 9.13 ± 7.62  
CYP2C19*2 11.14 ± p = 0.047 46.13 ± p = 0.270 10.72 ± p = 0.314 70.65 ± p = 0.167 4.90 ± 2.77 p = 0.060 8.93 ± 6.15 p = 0.006 8.61 ± 7.23 p = 0.936 
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rs4244285 
G/A 
6.03 18.76 5.65 37.36 
CYP2C19*2 
rs4244285 
A/A 
14.08 ± 
0.15 
 37.10 ± 
15.11 
 6.97 ± 
10.72 
 39.72 ± 
9.53 
 2.64 ± 1.07  3.32 ± 0.81  9.82 ± 7.28  
CYP2C19*17 
rs12248560C/
C 
10.67 ± 
5.77 
 43.86 ± 
18.72 
 10.70 ± 
6.47 
 71.19 ± 
44.01 
 5.17 ± 3.16  10.77 ± 
9.41 
 8.72 ± 6.87  
CYP2C19*17 
rs12248560C/
T 
10.89 ± 
6.31 
p = 0.231 43.57 ± 
17.87 
p = 0.148 10.69 ± 
9.69 
p = 0.485 69.93 ± 
40.10 
p = 0.930 5.22 ± 3.08 p = 0.018 10.74 ± 
8.95 
p = 0.510 9.68 ± 8.76 p = 0.745 
CYP2C19*17 
rs12248560T/
T 
12.13 ± 
3.83 
 34.54 ± 
13.70 
 9.64 ± 5.40  70.60 ± 
36.73 
 3.17 ± 1.81  7.55 ± 4.55  9.05 ± 6.21  
NAT2*5 
rs1801280  
T/T 
9.49 ± 5.37  45.45 ± 
18.31 
 11.01 ± 
6.51 
 85.82 ± 
50.09 
 6.17 ± 3.62  14.79 ± 
10.73 
 10.29 ± 
8.05 
 
NAT2*5 
rs1801280  
T/C 
11.23 ± 
5.76 
p = 0.003 42.89 ± 
17.45 
p = 0.306 10.40 ± 
5.94 
p = 0.181 66.83 ± 
36.50 
p < 0.001 4.74 ± 2.87 p < 0.001 9.21 ± 7.91 p < 0.001 8.84 ± 7.82 p = 0.019 
NAT2*5 
rs1801280  
C/C 
12.41 ± 
6.77 
 40.50 ± 
20.41 
 10.60 ± 
12.69 
 48.36 ± 
24.50 
 3.81 ± 1.43  5.50 ± 0.15  6.77 ± 3.90  
NAT2*6 
rs1799930  
G/G 
10.00 ± 
5.93 
 42.43 ± 
20.06 
 10.70 ± 
9.36 
 80.76 ± 
43.48 
 5.58 ± 3.34  12.63 ± 
9.53 
 10.39 ± 
8.22 
 
NAT2*6 
rs1799930  
G//A 
10.88 ± 
5.75 
p < 0.001 43.13 ± 
16.21 
p = 0.114 10.51 ± 
6.11 
p = 0.369 67.09 ± 
42.06 
p < 0.001 4.97 ± 3.03 p = 0.010 10.18 ± 
9.05 
p < 0.001 8.65 ± 7.20 p < 0.001 
NAT2*6 
rs1799930  
A/A 
13.48 ± 
5.67 
 48.42 ± 
19.08 
 10.88 ± 
5.55 
 47.52 ± 
26.65 
 3.92 ± 2.04  4.93 ± 3.87  5.60 ± 3.83  
NAT2*7 
rs1799931  
G/G 
10.79 ± 
6.17 
 
 
p = 0.049 
43.27 ± 
18.75 
 
 
p = 0.062 
10.26 ± 
7.61 
 
 
p = 0.093 
70.42 ± 
42.85 
 
 
p = 0.421 
5.19 ± 3.20  
 
p = 0.761 
10.79 ± 
9.26 
 
 
p = 0.087 
9.37 ± 7.70  
 
p = 0.026 
NAT2*7 
rs1799931  
G/A 
12.15 ± 
2.54 
 50.91 ± 
10.72 
 11.44 ± 
2.84 
 59.62 ± 
31.62 
 4.38 ± 1.40  6.03 ± 0.50  5.76 ± 3.60  
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Supplemental Figure S7: Scheme and linkage analysis of the CYP2C SNPs analyzed in this study. 
 
                                  
 
The linkage figure (left) and the haplotype figure (right) were composed with Haploview Ver. 4.1. The linkage figure was performed according to 
the standard colour scheme (D’/LOD), and the D’ values (x 100) are shown when relevant. The haplotype frequencies (right) indicate that the 
commonest CYP2C haplotype was the haplotype containing no variant alleles.  
 
2C19*17 2C19*2 2C19*3 2C9*2 C9*3 2C8*4 2C8*3 
36 
 
 
Supplemental Table S8: Effect of CYP2C haplotypes on metamizole metabolite recoveries and metabolic ratios. 
 
 MAA (mg) Intergroup 
comparison 
values 
FAA (mg) Intergroup 
comparison 
values 
AA (mg) Intergroup 
comparison 
values 
AAA (mg) Intergroup 
comparison 
values 
Formylatio
n ratio 
(FAA/MAA
) 
Intergroup 
comparison 
values 
Demethyla
tion ratio  
((AA+AAA
)/MAA)) 
Intergroup 
comparison 
values 
Acetylatio
n ratio 
(AAA/AA) 
Intergroup 
comparison 
values 
Non mutated 
homozygous 
n= 65 
10.41 ± 
6.33 
 
45.59 ± 
20.52 
 
11.81 ± 
6.39 
 
74.71 ± 
52.48 
 5.65 ± 3.33  
12.57 ± 
11.01 
 7.80 ± 6.59   
Non mutated / 
mutated 
n = 173 
10.67 ± 
6.30 
p = 0.146 
43.45 ± 
18.71 
p = 0.538 9.99 ± 6.34 p = 0.089 
69.34 ± 
42.87 
p = 0.677 5.32 ± 3.27 p = 0.016 
10.76 ± 
9.55 
p = 0.174 9.29 ± 7.74 p = 0.260 
Mutated 
Homozygous 
n = 124 
11.19 ± 
5.00 
 
42.20 ± 
16.44 
 
10.97 ± 
9.54 
 
70.37 ± 
35.43 
 4.51 ± 2.66  9.39 ± 7.01  9.31 ± 7.60  
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Supplemental table S9: Analysis of the differential effect of NAT2*5 and NAT2*6 alleles in the recoveries of MAA, AAA and the 
acetylation ratio. 
Genotype Number of 
individuals MAA (mg) 
Comparison 
(Mann-Whitney) AAA (mg) 
Comparison 
(Mann-Whitney) 
Acetylation ratio 
AAA/AA 
Comparison 
(Mann-Whitney) 
NAT2*4/*4 27 6.71  ± 3.02 reference value 123.90  ± 30.52 reference value 16.02  ± 10.12 reference value 
NAT2*4/*5 78 9.32 ± 5.04  p = 0.311 91.22  ± 38.91 
 
p = 0.173 10.66  ± 8.55 
 
p = 0.238 
NAT2*4/*6 69 8.34 ± 4.43  101.09  ± 46.82  11.07  ± 7.05  
NAT2*5/*5 57 12.49 ± 6.81  p = 0.155 49.70 ± 23.13 
 
p = 0.034 6.83 ± 3.91 
 
p = 0.004 
NAT2*6/*6 37 13.91 ± 5.66  40.88 ± 12.61  5.19 ± 3.68  
 
The differential effect of the slow alleles NAT2*5 and NAT2*6 on the recoveries of MAA and AAA, as well as the effect in the 
acetylation ratio was analyzed. The basal values for carriers of NAT2*4 (rapid alleles) in homozygosity are shown for reference. The 
comparison of the metabolite recoveries and the acetylation ratio between carriers of NAT2*5 and NAT2*6 in heterozygosity with 
NAT2*4 revealed non-significant differences in the effect of NAT2*5 and NAT2*6. However, when no NAT2*4 alleles were present, 
significant differences between homozygous carriers of NAT2*5 and homozygous carriers of NAT2*6 are observed for the recovery 
of AAA and for the acetylation ratio. NAT2*6 is associated to a higher impairment in the acetylation capacity as compared to 
NAT2*5, which is in agreement with previous findings obtained with a different NAT2 substrate [33]. 
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Supplemental table S10: Association between araquidonate metabolites and major metabolite recoveries and metabolic ratios in 55 healthy subjects. 
 
 ARA-MA 
(mg) 
ARA-NMA+ARA-MA 
(mg) 
MAA (mg) FAA (mg) AA (mg) AAA (mg) Formylation 
ratio 
(FAA/MAA) 
Demethylati
on ratio  
((AA+AAA)/
MAA)) 
Acetylation 
ratio 
(AAA/AA) 
ARA-NMA (mg) p < 0.001 p < 0.001 p < 0.001 p = 0.075 p = 0.398 p = 0.212 p = 0.002 p  < 0.001 p = 0.028 
ARA-MA (mg)  p < 0.001 p < 0.001 p = 0.014 p = 0.464 p = 0.242 p = 0.001 p < 0.001 p = 0.053 
ARA-NMA+ARA-MA (mg)   p < 0.001 p = 0.026 p = 0.451 p = 0.201 p = 0.001 p < 0.001 p = 0.038 
 
The significance values for bilateral Spearman correlations are shown. 
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Supplemental Table S11. Effect of non-genetic factors on araquidonate metabolites recoveries  
 
 ARA-NMA (mg) Intergroup comparison 
values 
ARA-MA (mg) Intergroup comparison 
values 
Men (n= 7) 0.49 ± 0.56 p= 0.382  0.74 ± 0.99 p = 0.515 
Women (n = 48) 0.70 ± 1.24  1.07 ± 2.33  
Age  p= 0.134  p = 0.263 
Weight  p = 0.805  p = 0.705 
Height  p = 0.090  p = 0.452 
Body mass index  p = 0.247  p = 0.450 
Urine volume (ml)  p = 0.107  p = 0.971 
Drinkers 0.69  ± 0.93 p = 0.039 0.93 ± 1.35 p = 0.001 
Non-drinkers 0.40 ± 0.56  0.43 ± 0.51  
Drinks per week  p = 0.414  p = 0.325 
Smokers 0.85 ± 1.15 p = 0.021 1.30 ± 1.73 p = 0.093 
Non-smokers 0.51 ± 0.69  0.72 ± 1.48  
Cigarettes per day   p= 0.978  p = 0.564 
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Supplemental Figure S12: Summary of the effects observed on the metabolic profiles of metamizole. 
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amino 
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(N)-
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